Physician profile
Amrou Sarraj
NPI 1518264514
$181,777.30
in general payments reported to CMS, 2019-2025
12 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141K · 2020: $18K · 2021: $7,059 · 2022: $489 · 2023: $15K · 2024: $81.94 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $740 · Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,245.00 |
| Travel and Lodging | $739.88 |
| Food and Beverage | $319.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $171,297.40 | 2019-2024 | Trevo, Neuroform Atlas, Fixos |
| Astrazeneca Pharmaceuticals Lp | $5,698.06 | 2021-2024 | Andexxa |
| Genentech, INC. | $3,679.75 | 2019-2023 | Tnkase |
| Viz.Ai, INC. | $695.48 | 2021-2022 | |
| Abbott Laboratories | $130.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $89.85 | 2021-2022 | |
| Csl Behring | $46.85 | 2025 | Kcentra, Privigen |
| Takeda Pharmaceuticals U.S.A., INC. | $46.07 | 2025 | Hyqvia |
| Ucb, INC. | $36.66 | 2025 | Briviact, Zilbrysq |
| Argenx US, INC. | $25.00 | 2022 | |
| Pfizer INC. | $18.24 | 2025 | |
| Neurelis, INC. | $13.60 | 2025 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrou Sarraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.